Medicare coverage for Gocovri (ριστιγμίνης παλμιτικό οξύ) is available for individuals with Parkinson's disease experiencing motor fluctuations [1]. Gocovri is indicated to treat dyskinesia in patients with Parkinson's disease who are on dopamine replacement therapy [2].
What are the specific Medicare coverage details for Gocovri?
Medicare Part B generally covers Gocovri when it is medically necessary and prescribed by a doctor for approved indications [1]. The out-of-pocket costs for beneficiaries can vary depending on their specific Medicare plan, such as Medicare Advantage or a Medicare Supplement plan, and whether they have met their deductible [1]. It is advisable for patients to verify coverage directly with their Medicare provider or Gocovri's patient assistance programs to understand their specific benefits and potential costs [1].
Are there other Parkinson's medications covered by Medicare?
Medicare covers a range of medications for Parkinson's disease beyond Gocovri. This includes levodopa and carbidopa, dopamine agonists, MAO-B inhibitors, and COMT inhibitors, among others [3]. The specific coverage for these medications also depends on the Medicare Part D plan or Medicare Advantage plan the beneficiary is enrolled in [3].
Where can I find information about Gocovri's patent and exclusivity?
Information regarding Gocovri's patent status and market exclusivity can be found through resources like DrugPatentWatch.com [4]. This site tracks patent filings, expirations, and other intellectual property details that can affect a drug's market availability and the potential for generic or biosimilar competition [4].